Sheng, Qing,Wang, Hui-Qin,Li, Fang,Liang, Jinsheng,Cao, Zhu Alexander,Monahan, John,Versace, Richard
申请号：
AU2017200232
公开号：
AU2017200232A1
申请日:
2017.01.13
申请国别(地区):
AU
年份:
2017
代理人:
摘要：
#$%^&*AU2017200232A120170202.pdf#####H: rbr Intrwoven NRPortbl DCC RBR I2746312 L.docx-13/01/2017 Abstract A pharmaceutical combination comprising (a) a compound of formula (1), R 2 R1 N (R4 - N R N N R 3 ,5 1 W (1) or pharmaceutically acceptable salts thereof； and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway； the uses of such combination in the treatment or prevention of proliferative diseases； and methods of treating a subject suffering from a proliferative disease； and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
